Right now in cyberspace: PREFER annual meeting 2020

Today and tomorrow, the PREFER consortium meets to discuss the final stage of the project and go through initial results from our case studies. We are also looking at what the outputs from the project will be and understand the EMA/EUnetHTA qualification concept of the framework for patient preference studies.

On day one, we focus on the PREFER case studies (Link removed) and what we have learned from them so far. With a special focus on how they can address the PREFER methodological research questions and inform our final recommendations.

On day two, we get a recap of what is currently happening with the PREFER final recommendations, operational guidance and training. And advice on how to work with patients as research partners in preference studies from PREFER researchers. Then, it’s time to discuss final recommendations, method comparisons, educational tools and more, before moving on to the EMA/EUnetHTA qualification concept for patient preference studies and methods.

Follow along on Twitter using the hashtag #PREFERvirtual2020!

Explore PREFER case studies (Link removed)

Explore PREFER publications (Link removed)





  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.


The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).